## Paul E Milligan

## List of Publications by Year in descending order

Source: https:|/exaly.com/author-pdf/7088587/publications.pdf
Version: 2024-02-01


```
        Maximal dose-response of vitamin-K2 (menaquinone-4) on undercarboxylated osteocalcin in women
        with osteoporosis. International Journal for Vitamin and Nutrition Research, 2020, 90, 42-48.
Maximal dose-response of vitamin-K2 (menaquinone-4) on undercarboxylated osteocalcin in women
with osteoporosis. International Journal for Vitamin and Nutrition Research, 2020, 90, 42-48.
```

0.6

8

Multifaceted approach to reducing occurrence of severe hypoglycemia in a large healthcare system.
$2 \quad$ Multifaceted approach to reducing occurrence of severe hypoglycem

Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. Thrombosis and
1.8

120
Haemostasis, 2014, 111, 88-93.

Risk factors for inpatient venous thromboembolism despite thromboprophylaxis. Thrombosis
0.8

42
Research, 2014, 133, 25-29.

Optimal Initial Dose Adjustment of Warfarin in Orthopedic Patients. Annals of Pharmacotherapy, 2007,
41, 1798-1804.
0.9

27

6 Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood, 2007, 110, 1511-1515.
$0.6 \quad 164$
$7 \quad$ Clinical classification schemes for predicting hemorrhage: Results from the National Registry of
7 Atrial Fibrillation (NRAF). American Heart Journal, 2006, 151, 713-719.
1.2

890

8 Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thrombosis and
Haemostasis, 2005, 93, 700-705.
1.8

176

9 Pharmacology and pharmacogenetics of warfarin and other coumarins when used with supplements.
9 Thrombosis Research, 2005, 117, 55-59.

Effect of warfarin nonadherence on control of the International Normalized Ratio. American Journal
10 Effect of warfarin nonadherence on control of the In
0.5

75

11 Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.
Thrombosis and Haemostasis, 2004, 91, 87-94.
1.8
0.4

30

14 Substitution of Generic Warfarin for Coumadin in an HMO Setting. Annals of Pharmacotherapy, 2002, 36, 764-768.

